ClinicoEconomics and Outcomes Research (Jul 2021)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]

  • Mareque M,
  • Montesinos P,
  • Font P,
  • Guinea JM,
  • de la Fuente A,
  • Soto J,
  • Oyagüez I,
  • Brockbank J,
  • Iglesias T,
  • Llinares J,
  • Sierra J

Journal volume & issue
Vol. Volume 13
pp. 645 – 646

Abstract

Read online

Mareque M, Montesinos P, Font P, et al. Clinicoecon Outcomes Res. 2021;13:263–277. Page 271, Results, Base Case, second line from the bottom, the text “€ 15,134” should read “€ 151,434”. The authors apologize for this error. Read the original article

Keywords